衰弱表型可预测接受直接口服抗凝药门诊患者的出血与死亡风险
该前瞻性队列纳入236例因房颤或静脉血栓栓塞症接受直接口服抗凝药治疗的门诊患者,按衰弱表型分为衰弱、衰弱前期和非衰弱。中位随访304天,衰弱患者临床相关出血和全因死亡风险显著高于衰弱前期及非衰弱患者,提示衰弱评估有助于识别高危患者。
要点
- 衰弱表型可识别接受直接口服抗凝药治疗的门诊患者中出血和死亡风险更高者。
- 衰弱患者不适当高剂量或低剂量使用直接口服抗凝药的比例高于非衰弱或衰弱前期患者。
- 非衰弱患者随访期间未发生临床相关出血、血栓栓塞或死亡结局。
核心结论
- 在因房颤或静脉血栓栓塞症接受直接口服抗凝药治疗的门诊患者中,衰弱表型识别出出血和全因死亡风险更高的患者。
- 衰弱评估可能有助于指导针对性干预以改善患者预后。
研究设计与样本
- 前瞻性连续纳入接受直接口服抗凝药治疗房颤或静脉血栓栓塞症的成人门诊患者。
- 共纳入236例患者,中位年龄78岁,女性占44%,其中房颤156例(66%)、静脉血栓栓塞症80例(34%)。
- 中位随访304天,研究结局为临床相关出血(包括大出血和临床相关非大出血)、动脉和静脉血栓栓塞症及全因死亡。
主要发现
- 衰弱患者临床相关出血、血栓栓塞和死亡发生率分别为20%、4%和9%,衰弱前期患者分别为10%、3%和2%,非衰弱患者无研究结局发生。
- 衰弱患者相对衰弱前期及非衰弱患者的临床相关出血风险比为2.5(95%CI 1.8–3.7)。
- 衰弱患者相对衰弱前期及非衰弱患者的血栓栓塞风险比为1.9(95%CI 0.9–4.0)。
- 衰弱患者相对衰弱前期及非衰弱患者的全因死亡风险比为6.3(95%CI 2.9–13.6)。
- 衰弱患者中不适当高剂量或低剂量使用直接口服抗凝药者占33%,非衰弱或衰弱前期患者中占20%。
临床怎么用
- 对接受直接口服抗凝药的老年门诊患者可考虑进行衰弱表型评估,以识别出血和死亡高危人群。
- 对衰弱患者应关注直接口服抗凝药剂量适当性,该研究中衰弱患者不适当剂量使用比例较高。
局限性
- 原文摘要未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Limited prospective data exist about the clinical relevance of frailty in patients with atrial fibrillation (AF) or venous thromboembolism (VTE) receiving direct oral anticoagulants (DOACs). The aim of this study was to evaluate whether frailty phenotype identifies DOAC-treated patients at higher risk of adverse clinical outcomes. METHODS: Consecutive, adult outpatients treated with DOACs for AF or VTE were prospectively enrolled. Patients were classified as frail, pre-frail, or non-frail according to frailty phenotype. Study outcomes were clinically relevant bleeding, including major and clinically relevant non-major bleeding, arterial and venous thromboembolism, and all-cause mortality. RESULTS: 236 patients (median age 78 years, 44% females) were included, of whom 156 (66%) had AF and 80 (34%) VTE. Ninety-eight (41%) patients were frail, 115 (49%) pre-frail, and 23 (10%) non-frail. Inappropriately high or low dose DOAC was used in 33% of frail and in 20% of non-frail or pre-frail patients. Over a median follow-up of 304 days, the incidence of clinically relevant bleeding, thromboembolism, and mortality were 20%, 4%, 9% in frail, and 10%, 3%, and 2% in pre-frail, respectively, while no study outcome occurred among non-frail patients. Risk ratios (95% confidence intervals) for these outcomes in frail versus pre-frail and non-frail patients were respectively 2.5 (1.8, 3.7), 1.9 (0.9, 4.0), and 6.3 (2.9, 13.6). CONCLUSION: In a prospective cohort of ambulatory patients receiving DOAC treatment for AF or VTE, frailty phenotype identified patients at higher risk of bleeding and all-cause mortality. Frailty assessment could be valuable to guide targeted interventions potentially improving patient prognosis.
引用
- Candeloro M, Di Nisio M, Potere N, et al. Frailty phenotype as a predictor of bleeding and mortality in ambulatory patients receiving direct oral anticoagulants. J Am Geriatr Soc. 2022. PMID: 35974661. doi:10.1111/jgs.18001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。